Ann: Kazia Annual Report to shareholders, page-4

And that’s the absolute strongest language supporting success to date...

many ‘deep divers’ and ‘dot connectors’ and ‘informal researchers + sharers’ we have here have been saying for a year or two that we on to something super special here and the standard industry % do not apply when you have so many boxes ticked and when the science community is so enthralled by the compound they as third-parties are willing to invest untold financial and human capital into our compound... and then continue to run programs when they do not have attachment to the compound beyond its ability to succeed!

there was more than smoke surrounding GDC-0084/Paxalisib there was obvious small fires burning brightly in top oncology labs around the world.

combine this with a solid management team to manage process and partnerships and strategy & solid science board to steer science direction, trials and compound selection and you have a potent combination punching well above their/our collective weight and the industry standards.

what a truly remarkable situation we find ourselves in

well done to the Kazia team and all those who have invested in their success and fund this journey through a few tough years - we are at the pointy end now

credibility is earned and you are judged by the friends you keep I think we have achieved credibility with Paxalisib and yet Cantrixil is also super exciting and is still progressing.... and we keep extremely good friends.

I’m very happy with progress as we all should be.